The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

Novartis and Novo helped provide $40m for the autoimmune disease therapy developer that supported its acquisition of joint venture Kanyos Bio.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Praktikertjänst-backed Aprea Therapeutics has filed for a $68.3m initial public offering that will fund the clinical progress of its cancer drug candidates.

The immuno-oncology drug developer, which counts numerous pharmaceutical firms among its investors, has filed for a $100m offering in the US.

Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

The corporate has bought portfolio company Kazan Networks three years after a series A round that also included Samsung Ventures and Intel Capital.

Microsoft and Qvest Media are set to exit video livestreaming technology developer in an acquisition by LTN Global.

Fosun Pharma is in line to exit Shanghai Henlius Biotech, which has set a price range for an offering that could raise up to $477m.

Spirogen spinoff ADC will put the proceeds into advancing its cancer-fighting antibody drug conjugates, having raised more than $530m from backers including AstraZeneca.